Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
Authors:
- On behalf of the European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy)O(On behalf of the European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy)
- C. De DivitiisCDC. De Divitiis
- C. von ArxCAC. von Arx
- A. M. GrimaldiAGA. M. Grimaldi
- D. CicalaDCD. Cicala
- F. TatangeloF. Tatangelo
- A. ArcellaAAA. Arcella
- G. M. RomanoGRG. M. Romano
- E. SimeoneESE. Simeone
- R. V. IaffaioliRIR. V. Iaffaioli
- P. A. AsciertoPAP. A. Ascierto
- S. TafutoSTS. Tafuto
Open Access
- 3 May 2016
- journal article
- case report
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 113
Abstract
Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine and nervous system. Most NETs have gastroentero-pancreatic (GEP) origin, arising in the foregut, midgut, or hindgut. The 2010 WHO classification divides GEP-NETs into two main subgroups, neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), according with Ki-67 levels. NET are tumors with low (20 %–G3). Poorly differentiated neuroendocrine carcinomas (NEC) are usually treated with cisplatin-based chemotherapy regimens. Here we present a case of a patient with pancreatic NEC progressing after cisplatin and etoposide, treated with temozolomide as palliative, second line treatment. According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m2/day—one-week-on/on-week-off). MGMT resulted methylated. On July 2014 the patient started the treatment. On August 2014 the patient obtained a significant clinical benefit (PS = 0) and the total body CT scan performed on October 2014 showed a RECIST partial response on all the sites of disease. No drug-related side effects were reported by the patient. After 18 months of therapy the treatment continues without significant toxicity, and with further remission of the metastases. Treatment with metronomic “one-week-on/on-week-off” Temozolomide can be considered a good treatment option in patients with poor performance status, affected by pNEC with MGMT methylation.Keywords
This publication has 38 references indexed in Scilit:
- Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsJournal of Translational Medicine, 2013
- Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter StudyCancer Research and Treatment, 2012
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumoursEndocrine-Related Cancer, 2012
- Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing MiceCancer Research, 2011
- Camouflage and sabotage: tumor escape from the immune systemCancer Immunology, Immunotherapy, 2011
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor ImmunityCancer Research, 2010
- Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma ModelClinical and Vaccine Immunology, 2010
- New (alternative) temozolomide regimens for the treatment of gliomaNeuro-Oncology, 2009
- Population-Based Study of Islet Cell CarcinomaAnnals of Surgical Oncology, 2007